The strongest claims come from canine-specific evidence, but that evidence is narrower than many people assume. In dogs, studies commonly use endpoints such as performance on cognitive or problem-solving tasks, owner-reported behavior changes, and objective activity measures (e.g., movement patterns or rest-activity cycles). These endpoints are meaningful, yet they are indirect: improved behavior or activity can reflect changes in arousal, sleep quality, pain, or mobility as much as changes in neuronal resilience.
Mechanistic biomarkers—oxidative status markers, inflammatory mediators, or metabolic readouts—can support plausibility, but they do not prove that neurons were “protected” in the strict histologic sense. Imaging and cerebrospinal fluid measures are less common in routine canine trials, and sample sizes are often modest, which limits statistical power and generalizability.
A large portion of mechanistic understanding is extrapolated from rodent and human neuroscience, especially for pathways involving mitochondrial biogenesis, redox signaling, and glial activation. Extrapolation requires caution because species differences in metabolism, brain aging trajectories, dosing, and blood-brain barrier transport can change both effect size and safety profile.
Key unknowns include which subpopulations of dogs respond best, how durable effects are after stopping an intervention, and whether short-term endpoint improvements track with long-term neurodegenerative risk reduction—questions that require longer, well-controlled canine studies.
